Uncategorized
Lucentis receives FDA approval to treat myopic choroidal neovascularization
Genentech announced the FDA approved Lucentis for the treatment of myopic choroidal neovascularization, the fifth FDA-approved indication for the drug. In the phase 3 RADIANCE study, Lucentis (ranibizumab) provided an average visual acuity gain of more than 12 letters for patients with myopic CNV after 3 months of treatment, compared with 1.4 letters for those treated with verteporfin photodynamic therapy. The randomized, double-masked, active-controlled study compared the safety and efficacy of ranibizumab and verteporfin PDT in 276 patients with myopic CNV, according to a company press release.